ArticleJournal of neuro-oncology2016
Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma.International journal of translational medicine (Basel, Switzerland) · 2025Article
- Article
- Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting.Journal of the National Cancer Institute · 2025Article
- Current status of precision oncology in adult glioblastoma.Molecular oncology · 2024Review
- Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.Journal of cancer research and clinical oncology · 2023Article
- Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.PloS one · 2023Article
- Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma.International journal of molecular sciences · 2022Article
- Article
- Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.BMC cancer · 2020Article
- Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.Nature communications · 2020Article
- An ErbB2 splice variant lacking exon 16 drives lung carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.BMC cancer · 2020Article
- How We Treat Recurrent Glioblastoma Today and Current Evidence.Current oncology reports · 2019Review
- The current state of molecular testing in the treatment of patients with solid tumors, 2019.CA: a cancer journal for clinicians · 2019Review
- Comparative proteogenomic characterization of glioblastoma.CNS oncology · 2019Article
- Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.Journal of neuro-oncology · 2019Article
- Fibroblast growth factor receptors as treatment targets in clinical oncology.Nature reviews. Clinical oncology · 2019Review
- WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.BMC cancer · 2018Article
- Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor.Journal of Korean Neurosurgical Society · 2018Review
- Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomic research of high grade glioma (HGG) has revealed complex biology with potential for therapeutic impact. However, the utilization of this information and impact upon patient outcome has yet to be assessed. We performed capture-based next generation sequencing (NGS) genomic analysis assay of 236/315 cancer-associated genes, with average depth of over 1000 fold, to guide treatment in HGG patients. We reviewed clinical utility and response rates in correlation to NGS results. Forty-three patients were profiled: 34 glioblastomas, 8 anaplastic astrocytomas, and one patient with anaplastic oligodendroglioma. Twenty-five patients were profiled with the 315 gene panel. The median number of identified genomic alterations (GAs) per patient was 4.5 (range 1-23). In 41 patients (95 %) at least one therapeutically-actionable GA was detected, most commonly in EGFR [17 (40 %)]. Genotype-directed treatments were prescribed in 13 patients, representing a 30 % treatment decision impact. Treatment with targeted agents included everolimus as a single agent and in combination with erlotinib; erlotinib; afatinib; palbociclib; trametinib and BGJ398. Treatments targeted various genomic findings including EGFR alterations, mTOR activation, cell cycle targets and FGFR1 mutations. None of the patients showed response to respective biologic treatments. In this group of patients with HGG, NGS revealed a high frequency of GAs that lead to targeted treatment in 30 % of the patients. The lack of response suggests that further study of mechanisms of resistance in HGG is warranted before routine use of biologically-targeted agents based on NGS results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.